AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05784701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSCV (Half-strength)
Description: TSCV (Half-strength)
Study NCT05784701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typbar-TCV
Description: Typbar-TCV
Study NCT05784701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06097234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelex Upp
Description: Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.
Study NCT06097234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
Study NCT05159843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise
Study NCT05276804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
Study NCT04731844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin plus Piperine
Description: Curcumin with piperine is a well-tolerated over-the-counter supplement.
Study NCT05346627 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Personalized and mixed training program
Description: Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
Study NCT06372756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning image reconstruction
Description: Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.
Study NCT05701657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet A
Description: This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, nuts/seeds, and olive oil, and very low amounts of sugar sweetened drinks and desserts. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
Study NCT05701657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet B
Description: This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
Study NCT05701657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet C
Description: This diet has moderate-high amounts of vegetables, meat/poultry/egg, nuts/seeds, dairy and fats/oils, low amounts of fruits, and very low amounts of grains and sugars. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
Study NCT05701657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liquid Mixed Meal Tolerance Test
Description: A liquid mixed meal tolerance test will occur in Module 1 and Module 3. For this test, participants will drink two servings of Ensure® Original, vanilla flavor. The meal will also contain acetaminophen (Tylenol) which will show how the smoothie moves through the participant's gut.
Study NCT05701657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet-Specific Mixed Meal Tolerance Test
Description: The diet-specific mixed meal tolerance test is administered at the end of each dietary intervention period in Modules 2 and 3. The meal test is a breakfast meal similar to the one eaten on the 14-day diets. Thus, three test meals will be used, one for each of the three test diets (Diet A, Diet B, Diet C). The energy (kcal) level of the breakfast meal will be based on each participant's diet prescription. The nutritional composition diet-specific MMTT will be the same test meal for all participants.
Study NCT05457296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (capsule)
Description: salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
Study NCT05457296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone (capsule)
Description: salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
Study NCT06330363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: The Cube plus30 from Eltech K-Laser s.r.l. (Italy, www.k-laser.com) will be used for LLLT. The laser devices from Eltech K-Laser s.r.l. have been used in (clinical) studies with a variety in patient populations (38-41) and clinical practice (https://resources.k-laser.com.au/medical-laser-clinical-applications). The device is a registered medical device in the EU confirmed by Kiwa Cermet Italia.
Study NCT06330363 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The laser device has sham light option that will be used.
Study NCT01624532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1109 or Placebo of GC1109
Description: Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks.
Study NCT01624532 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GC1109 or Placebo of GC1109
Description: Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks.
Study NCT05450822 — intervention group
Intervention type: DRUG
Intervention: Levetiracetam
Description: Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models.
Study NCT05450822 — intervention group
Intervention type: DRUG
Intervention: Levetiracetam Tablets
Description: Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
Study NCT05450822 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine tablet
Description: Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
Study NCT05071105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.
Study NCT05666401 — intervention group
Intervention type: PROCEDURE
Intervention: follicle diameter and duration of procedure
Description: to investigate if smaller follicles thrive embryos as the bigger follicles
Study NCT04942275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-therapeutic imaging test
Description: The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
Study NCT05172505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prefrontal tDCS
Description: 2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
Study NCT05172505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: prefrontal tDCS
Description: 2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
Study NCT05686304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help money management program
Description: The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
Study NCT05406544 — intervention group
Intervention type: OTHER
Intervention: FD qualitative study on quality of life
Description: Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
Study NCT05406544 — intervention group
Intervention type: OTHER
Intervention: FD quantitative sudy on quality of life and olfaction.
Description: Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
Study NCT05053386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride for Injection
Description: After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
Study NCT05053386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
Study NCT05001789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogMed
Description: 20 sessions of Cogmed working memory training
Study NCT05001789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CogMed
Description: 20 sessions of Cogmed working memory training
Study NCT05731973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoablation
Description: Intercostal nerve cryoablation is applied during Nuss procedure.
Study NCT05731973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))
Description: Thoracic epidural is placed prior to Nuss procedure
Study NCT05731973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))
Description: Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
Study NCT05731973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)
Description: Opioids
Study NCT05731973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)
Description: Opioids
Study NCT06079411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality non-embodied
Description: the non-embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
Study NCT06079411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality embodied
Description: the embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
Study NCT06079411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises
Study NCT05270889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab+Zanidatamab
Description: Zanidatamab will be administered at a flat dose as follows:~* Subjects with body weight \<70 kg: 1800 mg IV on Day 1 of each 21-day cycle~* Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle.
Study NCT04865835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo
Study NCT04865835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: single dose of SEP 363856 100 mg
Study NCT04865835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin-HCl 850 mg
Study NCT04865835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: metformin-HCl 850 mg
Study NCT05682482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LT3 (liothyronine)
Description: Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
Study NCT05682482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
Study NCT05391217 — intervention group
Intervention type: OTHER
Intervention: Remote assessment of patient reported outcomes and daily activity
Description: Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
Study NCT05560594 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast SpeediCath CH12 standard male intermittent catheter
Description: Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
Study NCT06199518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)
Description: extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
Study NCT04874311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
Study NCT04874311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
Study NCT04874311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
Study NCT05059457 — intervention group
Intervention type: DEVICE
Intervention: Blood source: single and pooled capillary and venous blood
Description: * A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.
Study NCT05059457 — intervention group
Intervention type: DEVICE
Intervention: Blood source: single capillary and venous blood
Description: * A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.
Study NCT05059457 — intervention group
Intervention type: DEVICE
Intervention: Blood source: pooled capillary and venous blood
Description: * Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.
Study NCT06292143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advance Care Planning Toolkit
Description: Participants or their caregivers will access the digital platform for advance care planning
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: 900 mg intravenously (IV) every 3 weeks (Q3W)
Study NCT05809895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ociperlimab
Description: 900 mg intravenously (IV) every 3 weeks (Q3W)
Study NCT06566638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NucleoCapture device
Description: 100ml NucleoCapture selective DNA adsorber.
Study NCT06565533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrogressive imagery (RETI)
Description: Week 1-2: Participants were asked to imagine a complete version of the FT imagery script included: a) Visualizing the court lines, the basket, and themselves standing at the free-throw line, focusing on their shooting technique. b) Imagining teammates and opponents positioned around the key, noting the main colors in the scene c) Imagining the coach standing on the sideline encouraging them, and paying attention to the sounds of the audience and the cheers from a close friend in the stands. d) Visualizing a high-pressure situation, experiencing the emotions felt during a real game with one second left on the clock, trailing by one point, with the game's outcome depending on their FT shot. Week 3-4: The exception of content dfrom the full script. Week 5-6: The exception of content cdfrom the full script. Week 7-8: The exception of content bcdfrom the full script.